Abstract
IntroductionInfliximab (IFX) dose escalation (DE) can be used in patients with inflammatory bowel disease with loss of response (LOR) or subtherapeutic drug levels. However, the long-term benefit of DE remains...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
